The baseline and on-treatment frequency of tumor antigen-specific CD8+ T cells in the tumor microenvironment and increased levels of interferon-γ (IFN-γ) at baseline are associated with a response to anti-PD-1-therapy in stage III and IV melanoma patients [2,3,4]. The gene discussed is PDCD1; the disease is neoplasm.